Intraperitoneal Radioactive Chromic Phosphate is a Well-Tolerated Adjuvant Treatment in Patients with Endometrial Cancer

Abstract

Abstract

Background: The data assessing overall survival with regard to different adjuvant treatment in the setting of advanced-stage endometrial cancer are limited, as such, the appropriate adjuvant therapy for patients with this condition remains unclear. Objective: The purpose of this study was to evaluate outcomes and demographics of patients with endometrial cancer who received intraperitoneal radioactive chromic phosphate (³²P) as part of their cancer treatment. Materials and Methods: This single-institution retrospective review ran from January 2005 to December 2009. All patients underwent comprehensive surgical staging followed by infusion of intraperitoneal ³²P and possible chemotherapy, hormonal therapy, or radiation treatment. The follow-up time period ranged from 20 to 68 months. Results: Eight patients with stage III node-negative endometrial cancer with positive cytology who received ³²P were identified. The mean follow-up was 45.4 months. The mean time from surgery to intraperitoneal ³²P was 4 months. Seven of 8 patients received adjuvant single-agent platinum or combination platinum/taxane chemotherapy. No grade 3 or 4 complications were noted. There has been no evidence of recurrent disease in these patients noted to date. Conclusions: Adjuvant intraperitoneal ³²P for treating endometrial cancer patients at risk for intraperitoneal recurrence is well-tolerated with minimal toxicity. (J GYNECOL SURG 31:67)